drugset / Trial / NCT00479297

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

NCT00479297

Phase 1 Completed 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending single oral doses of SAM-531, an investigational drug, in healthy Japanese male subjects. Secondary: To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-531 in healthy Japanese male subjects.

Timeline

Start
2006-05
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule Oral

Indications